

B	Investor Complaints	3 Months ended 30.09.2015
	Pending at the beginning of Quarter	-
	Received During the Quarter	26
	Disposed Off During the Quarter	26
	Pending at the end of Quarter	-

Statement of Assets and Liabilities		(Rs in Lacs)	
PARTICULARS	As at	As at	
	30-09-15	31-03-15	
	Unaudited	Audited	
SHAREHOLDERS' FUND			
(I) Capital	2,242.61	2,242.61	
(ii) Reserves and Surplus	97,026.03	93,552.29	
NON CURRENT LIABILITIES			
(i) Long Term Liabilities	28,027.46	26,552.92	
(ii) Deffered Tax Liability	11,726.07	11,019.28	
(iii) Other Long Term Liabilities	1,763.73	1,518.72	
(iv) Long Term Provisions	664.40	601.13	
CURRENT LIABILITIES			
(i) Short Term Borrowings	59,510.14	59,529.78	
(ii) Trade Payables	43,187.06	45,557.72	
(iii) Other Current Liabilities	11,751.38	9,050.00	
(iv) Short Term Provisions	1,790.82	1,422.15	
Total	257,689.70	251,046.60	
NON CURRENT ASSETS			
(i) Fixed Assets (Incl CWIP)	102,078.18	102,504.37	
(ii) Non Current Investments	5.01	5.01	
(iii) Long Term Loans & Advances	8,263.30	8,044.27	
(iv) Other Non Current Assets	5,324.79	3,591.24	
CURRENT ASSETS			
(i) Current Investments	43.51	43.51	
(ii) Inventories	81,938.70	79,097.46	
(iii) Trade Receivables	43,736.79	44,649.64	
(iv) Cash & Bank Balances	2,626.31	3,338.20	
(v) Short Term Loans & Advances	11,294.76	8,143.15	
(vi) Other Current Assets	2,378.35	1,629.75	
Total	257,689.70	251,046.60	

Notes:

- The above financial results were reviewed by Audit Committee on 12.11.15 and approved by the Board in its meeting held on even date i.e. 13.11.15 and further limited reviewed by the Statutory Auditors of the Company.
- The company is exclusively in the pharmaceutical business segment.
- The Shareholders in their Annual General Meeting held on 30.09.2015 have declared the final dividend of Re. 0.10/- per equity share (10% on the face value of Re. 1/- per equity share) for the financial year 2014-15. The Company has despatched Dividend Warrants to the shareholders at their registered addresses, and wherever applicable, the Dividend has been credited to the shareholders' accounts directly through National Electronic Credit Settlement (NECS/ECS/NEFT/ Direct Credit) facility of RBI.
- Previous year figures have been regrouped and reclassified wherever necessary to make them comparable with current period.
- The above financial results are on stand alone basis.

By Order of the Board of Directors
of Nectar Lifesciences Limited
sd/-

Dated: 13.11.15
Place: Chandigarh

(Dinesh Dua)
Chief Executive Officer & Director